Kenvue Inc. (KVUE)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Kenvue as a steady consumer health business, not a fast compounder. In fiscal Q2 2026, the quarter ended 2026-06-28, revenue was $4.0 billion, net income $456 million, and diluted EPS $0.24; in fiscal Q2 2025, the quarter ended 2025-06-29, those were $3.8 billion, $420 million, and $0.22. That is modest progress. For fiscal year 2025, period ended 2025-12-28, revenue was $15.1 billion, net income $1.5 billion, and diluted EPS $0.76; for fiscal year 2024, period ended 2024-12-29, revenue was $15.5 billion, net income $1.0 billion, and diluted EPS $0.54. Revenue slipped while profit recovered, which is not yet durable growth. The computed Lynch category calls it a slow grower, shrinking: profit -8.3% a year over four years and revenue 0.1%, so I am cautious. At the $19.50 close on 2026-10-26, FairStock shows P/E 22.94, P/B 3.55, FCF yield 5.1%, dividend yield 4.72%, and ROCE 6.99%. The Graham Number is $10.26, leaving the price 90.74% above that conservative value. Debt/equity is 0.82 and Altman Z is 1.63. Consumer health categories and scale help, but low returns on capital and flat sales suggest no wide moat. The dividend and cash flow are real, but the price offers no margin of safety; I would want either a lower price or clear evidence of durable revenue and profit growth.

In plain English: Kenvue sells everyday consumer health products such as over-the-counter medicine and skin care. The business looks only fair: sales have been roughly flat over recent years and debt is meaningful, but cash flow is positive and the dividend is high. At $19.50, the price looks expensive versus a conservative accounting value, so it does not scream bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-28) · fiscal Q1 2026 10-Q (period ended 2026-03-29) · fiscal Q3 2025 10-Q (period ended 2025-09-28) · fiscal Q2 2025 10-Q (period ended 2025-06-29) · FY2025 10-K (period ended 2025-12-28) · FY2024 10-K (period ended 2024-12-29) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer